In this study, we systematically investigated the effects of venetoclax (BCL-2), S63845 (MCL-1), and A-1331852 (BCL-XL) side-by-side in BCP-ALL, identifying heterogeneous sensitivities of all three inhibitors. Here, BCL2 is linked to acute lymphoblastic leukemia.